Skip to main content

Table 2 Selected demographic and baseline characteristics of the patients

From: Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience

Categorical factor No dose reduction (N=74) Dose reduction (N=49) p-value1
  N(row%) N(row%)  
Her2    
Negative 64 (63) 38 (37) 0.23
Positive 10 (48) 11 (52)  
Agent    
Paclitaxel only 28 (61) 18 (39) 0.572
Docetaxel only 45 (64) 25 (36)  
Multiple agents3 1 (14) 6 (86) 0.023
Alcohol    
No 71 (60) 47 (40) 1.00
Yes 3 (60) 2 (40)  
Diabetes    
No 67 (65) 36 (35) 0.02
Yes 7 (35) 13 (65)  
Race    
Black 40 (57) 30 (43) 0.574
White 30 (63) 18 (37)  
Other 4 (80) 1 (20)  
Continuous factor Mean (range) Mean (range)  
Age (years) 53 (32–78) 55 (35–75) 0.23
  1. 1p- values calculated with the use of two-sided Fisher’s and Fisher-Freeman-Halton’s tests for categorical variables and the t-test for continuous variables.
  2. 2Patients treated with paclitaxel (or nab- paclitaxel) only vs. those treated with docetaxel only.
  3. 3Patients treated with multiple agents, compared to those treated with either paclitaxel only or docetaxel only.
  4. 4Black compared to white only.